Neonatal Abstinence Syndrome (NAS) has been costly for the healthcare system; every 19 minutes, a newborn was diagnosed in 2021. Medically Assisted Treatment (MAT)) for expecting mothers has been shown to decrease costs and length of stay for newborns NAS. This study utilized a literature review and a semi-structured interview. The research showed that medically assisted treatment with methadone or buprenorphine during pregnancy decreased costs, LOS, and severity of symptoms for newborns diagnosed with NAS. The findings showed a positive association between lower costs for the initial stay of infants whose mothers received MAT. MAT during pregnancy has been shown to correlate positively with a shorter initial LOS for infants with NAS.
Stanfield, K., Day, K., Clemente, S. M. Coustasse, A. (2023, March 24). “Neonatal Abstinence Syndrome: An Update on the Cost and Length of Stay Associated with Treatment during the Hospital Stay.” Presented at MBAA International, Chicago, IL.